1186P Impact of temozolomide (TEM) and capecitabine (CAP) dose reductions in toxicity and efficacy in patients (pts) with neuroendocrine neoplasms (NENs) treated with CAPTEM chemotherapy.
Saved in:
| Title: | 1186P Impact of temozolomide (TEM) and capecitabine (CAP) dose reductions in toxicity and efficacy in patients (pts) with neuroendocrine neoplasms (NENs) treated with CAPTEM chemotherapy. |
|---|---|
| Authors: | Hernando, J.1 (AUTHOR), Garcia-Alvarez, A.1 (AUTHOR), Castaneda, D.H. Marmolejo1 (AUTHOR), Eyzaguirre, D.A. Acosta1 (AUTHOR), Garcia, M. Diez1 (AUTHOR), Gonzalez, N. Saoudi1 (AUTHOR), Casteras, A.2 (AUTHOR), Simo, M.3 (AUTHOR), Burillo, A. Garcia3 (AUTHOR), Merino, X.4 (AUTHOR), Blanco, L.5 (AUTHOR), Sanchez, J.L.5 (AUTHOR), Roca, M.1 (AUTHOR), Capdevila, J.1 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS782-S782. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
